In recent decades, our understanding of psoriasis has shifted from viewing it as solely a hyperproliferative skin condition to recognizing its immune-mediated origins. The discovery of cytokine pathways, particularly IL-23’s role in activating the Th17 pathway, has led to the development of targeted biologic therapies that specifically inhibit cytokines like IL-17 and TNF-α. This approach represents a significant advancement over older, less targeted treatments, enhancing both efficacy and safety by minimizing broad immunosuppression, thereby transforming the management of moderate-to-severe psoriasis.

The psoriasis treatment landscape has expanded significantly with over 13 FDA-approved biologics and novel topical and oral therapies. Ongoing research into biomarkers and personalized medicine aims to refine treatment strategies and address challenges like nail psoriasis and treatment accessibility, ensuring continuous innovation in psoriasis care.

Reference: Brownstone N. Psoriasis Therapies in 2024 and Beyond. Dermatology Times. Published January 16, 2024. Accessed June 18, 2024. https://www.dermatologytimes.com/view/psoriasis-therapies-in-2024-and-beyond